1. Impact Of Cyp3A5 Gene Polymorphism On Tacrolimus Pharmacokinetics In Kidney Transplant Patients

Authors

  • B.B. Baimakhanov JSC «National Scientific Center of Surgery named after A.N. Syzganov», Almaty, Kazakhstan
  • A.T. Chormanov JSC «National Scientific Center of Surgery named after A.N. Syzganov», Almaty, Kazakhstan
  • R.P. Ibragimov JSC «National Scientific Center of Surgery named after A.N. Syzganov», Almaty, Kazakhstan
  • I.K. Madadov JSC «National Scientific Center of Surgery named after A.N. Syzganov», Almaty, Kazakhstan
  • K.S. Dabyltaeva JSC «National Scientific Center of Surgery named after A.N. Syzganov», Almaty, Kazakhstan
  • Zh.M. Syrymov JSC «National Scientific Center of Surgery named after A.N. Syzganov», Almaty, Kazakhstan

Downloads

Abstract

Nowadays in Kazakhstan there is an active development of organ transplantation, particularly kidney transplantation. The main purpose is not only to save as much lives as possible but also improve the survival rates of graft. In this way, now we are investigating personalization and rationalization of immunosuppressive treatment. In our country as in whole world genetic factors, determinating long-term graft survival, represent a great relevancy in transplantation. According to the results of clinical trial, there is a strict association between CYP3A5 (сytochrome P450) genetic polymorphism and tacrolimus pharmacokinetics. The determination of genetic polymorphism of CYP 3A5 gives us the opportunity to predefine the changes in blood concentrations of tacrolimus, better control of immunosuppressive therapy, that will positively affect the long-term graft survival.

Keywords

tacrolimus, kidney transplantation, genetic polymorphism, immuno-suppressive

References

  1. Glowacki F, Lionet A, Buob Det al. «CYP3A5 and ABCB1 polymorphisms in donor and recipient: im-pact on Tacrolimus dose requirements and clinical outcome after renal transplantation». Nephrology Di-alysis Transplantation.
  2. Fan B, Qiu K, Jiang Y, Hu X, Yin H. «Prograf produces more benefits for CYP3A5 low expression patients in early stage after kidney transplantation». Biomed Pharmacotherapy.
  3. Cheng Y, Li H, Meng Y, Liu H «Effect of CYP3A5 poly-morphism on the pharmacokinetics of tacrolimus and acute rejection in renal transplant recipients: experi-ence at a single centre». International Journal Clini-cal Practice Supply. 2015 May. P. 16-22
  4. Quteineh L, Verstuyft C, Furlan V et al. «Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients» Basic Clinical Pharmacologic Toxicology.
  5. Shi Y, Li Y, Tang J, Zhang J et al. «Influence of CYP3A4, CYP3A5 and MDR-1 polymorphisms on tacrolimus pharmacokinetics and early renal dysfunction in liver transplant recipients». Gene. 2013 . P. 226-231
  6. Provenzani A, Notarbartolo M, Labbozzetta M et al. «Influence of CYP3A5 and ABCB1 gene polymor-phisms and other factors on tacrolimus dosing in Caucasian liver and kidney transplant patients». International Journal of Molecular Medicine. 2011/ P.1093-1102
  7. Zhang X, Liu ZH, Zheng JM, Chen ZH, Tang Z, Chen JS, Li LS. « Influence of CYP3A5 and MDR1 polymor-phisms on tacrolimus concentration in the early stage after renal transplantation». Clinical Transplantation. 2005, P. 638-643

Published

2019-04-01

Issue

No. 1 (2019)

Section

Статьи